Michelle Long
Company: Novo Nordisk
Job title: International Medical Vice President, NASH
Seminars:
Moving Beyond GLP1: Disentangling a FGF21 & GLP-1 Combination Therapy 11:30 am
Discussing the synergies between the different mechanisms of action to target NASH Outlining the current trial design Unravelling the challenges and opportunities of moving into further developmentRead more
day: Day 1 Seminar B Pre-Lunch Tracks
Exploring the Next Generation of Combination Therapies & Assessing Their Safety in Clinical Trials
Track Moderators: 10:59 am
Track Moderators:
day: Day 1 Seminar B Pre-Lunch Tracks
Chair’s Opening Remarks 8:25 am
day: Conference Day 1